title: Potential of CeCl3@mSiO2nanoparticles in alleviating diabetic cataract development and progression.
abstract: Cataract is a major cause of visual impairment for diabetic patients. It is imperative to develop efficient therapeutic agents against diabetic cataract (DC) because diabetes confers higher risk for complications after cataract surgery. We have previously reported the role of CeCl3loaded mesoporous silica (CeCl3@mSiO2) nanoparticles in reducing the oxidative stress of lens epithelial cells. However, the potential of CeCl3@mSiO2in preventing diabetic cataract development remains unclear. In this study, we applied CeCl3@mSiO2nanoparticles with a size of 87.6±8.9nm to streptozotocin-induced diabetic cataract rat model by intraperitoneal injection. Our results showed that CeCl3@mSiO2efficiently ameliorated the progression of DC. Consistent with antioxidant effect of CeCl3@mSiO2in vitro, administration of CeCl3@mSiO2significantly abrogated hyperglycemia-mediated upregulation of advanced glycation end products, lipid peroxidation and protein carbonylation in animal lens. Taken together, our study provides a potential nanodrug to manage the development of DC.
authors.affiliation: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Myopia Key Laboratory of Health PR China, Shanghai, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Yang
authors.affiliation: School of Life Sciences, Tianjin University, Tianjin Engineering Center of Micro-Nano Biomaterials and Detection-Treatment Technology, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China. Electronic address: gongxiaoqun@tju.edu.cn.
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Gong
authors.affiliation: School of Life Sciences, Tianjin University, Tianjin Engineering Center of Micro-Nano Biomaterials and Detection-Treatment Technology, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Fang
authors.affiliation: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Myopia Key Laboratory of Health PR China, Shanghai, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Fan
authors.affiliation: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Myopia Key Laboratory of Health PR China, Shanghai, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Cai
authors.affiliation: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Myopia Key Laboratory of Health PR China, Shanghai, China.
authors.forename: Xiaodi
authors.initials: X
authors.lastname: Qiu
authors.affiliation: School of Life Sciences, Tianjin University, Tianjin Engineering Center of Micro-Nano Biomaterials and Detection-Treatment Technology, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.affiliation: School of Life Sciences, Tianjin University, Tianjin Engineering Center of Micro-Nano Biomaterials and Detection-Treatment Technology, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin, China. Electronic address: jinchang@tju.edu.cn.
authors.forename: Jin
authors.initials: J
authors.lastname: Chang
authors.affiliation: Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Myopia Key Laboratory of Health PR China, Shanghai, China. Electronic address: luyieent@126.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Lu
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D002386:Cataract / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002563:Cerium / Q000008:administration & dosage / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D004337:Drug Carriers / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000378:metabolism; D007908:Lens, Crystalline / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D018384:Oxidative Stress / Q000187:drug effects; D016062:Porosity; D050050:Protein Carbonylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D000975:Antioxidants; D004337:Drug Carriers; D017127:Glycation End Products, Advanced; D002563:Cerium; D012822:Silicon Dioxide; C026690:cerous chloride
keywords: CeCl(3)@mSiO(2); Diabetic cataract; Glutathione; Oxidative stress